<SEC-DOCUMENT>0001193125-24-167211.txt : 20240625
<SEC-HEADER>0001193125-24-167211.hdr.sgml : 20240625
<ACCEPTANCE-DATETIME>20240624203228
ACCESSION NUMBER:		0001193125-24-167211
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240624
FILED AS OF DATE:		20240625
DATE AS OF CHANGE:		20240624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241065973

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d717414d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as June 24, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d717414dex991.htm">Immutep completes underwritten retail entitlement offer. </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 24, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d717414dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g717414g63s00.jpg" ALT="LOGO" STYLE="width:8.58542in;height:1.33958in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOT FOR DISTRIBUTION OR RELEASE TO U.S. WIRE SERVICES IN THE UNITED STATES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24&nbsp;June 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep completes
underwritten retail entitlement offer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep Limited ACN 009 237 889 (ASX: IMM) (<B>Immutep </B>or the <B>Company</B>) is pleased to announce the
completion of the retail component of its fully underwritten Entitlement Offer (details of which were announced to the market on 3&nbsp;June 2024) (<B>Retail Entitlement Offer</B>) which raised approximately A$10.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Retail Entitlement Offer took place in conjunction with a fully underwritten placement to institutional investors (<B>Placement</B>) and 1 for 16 pro rata
accelerated <FONT STYLE="white-space:nowrap">non-renounceable</FONT> entitlement offer (<B>Entitlement Offer</B> and, together with the <B>Placement</B>, the <B>Offer</B>) of new fully paid ordinary shares (<B>New Shares</B>) to raise approximately
$100.2&nbsp;million. The Placement and institutional component of the Entitlement Offer were successfully completed, raising approximately $89.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Retail Entitlement Offer allowed eligible retail shareholders in the Company (<B>Eligible Retail Shareholders</B>) the opportunity to subscribe for 1 New
Share for every 16 existing fully paid ordinary shares which they held in Immutep as at 7.00pm (Sydney, Australia time) on Wednesday, 5&nbsp;June 2024 at a price of A$0.38 per New Share, and also the opportunity to apply for additional New Shares in
excess of their entitlement (<B>Additional New Shares</B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Retail Entitlement Offer closed at 5.00 pm (Sydney, Australia time) on Thursday,
20&nbsp;June 2024 and a total of 1,963 valid applications for retail entitlements were received raising approximately A$4.4&nbsp;million. Eligible Retail Shareholders also applied for and were allocated a further approximately A$2.3&nbsp;million
worth of Additional New Shares. Total eligible applications under the Retail Entitlement Offer of approximately A$6.7&nbsp;million represents a total <FONT STYLE="white-space:nowrap">take-up</FONT> rate by Eligible Retail Shareholders of 62%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with the Placement and the institutional component of the Entitlement Offer, the total amount raised under the Offer, which was fully underwritten,
is approximately A$100.2&nbsp;million.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Russell Howard, Chairman of Immutep, said: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Immutep is pleased to have the continuing support of many long-term and existing shareholders who have participated in our Retail Entitlement Offer on
the same terms as our institutional investors. We have a very exciting path ahead as we advance toward marketing approval for efti through our late-stage clinical trial program. This includes our Phase III trial in lung cancer being conducted under
our third collaboration with MSD. We look forward to sharing news and milestones with all our shareholders as we move forward.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shortfall after
the issue of the New Shares and Additional New Shares<B> </B>under the Retail Entitlement Offer will be allocated to the sole underwriter of the Offer. The shortfall is comprised of entitlements not taken up by Eligible Retail Shareholders (or in
the case of retail shareholders who were ineligible to participate in the Retail Entitlement Offer, in respect of their entitlements which would otherwise have been available to them). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The settlement date for New Shares and Additional New Shares to be issued under the Retail Entitlement Offer is Tuesday, 25&nbsp;June 2024 and the issue of
New Shares and Additional New Shares under the Retail Entitlement Offer is scheduled to occur on Wednesday, 26&nbsp;June 2024, with those shares expected to commence trading on the ASX on Thursday, 27&nbsp;June 2024. New Shares and Additional New
Shares issued under the Retail Entitlement Offer will rank equally in all respects with existing ordinary shares on issue in Immutep with effect from their date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As announced to ASX on Monday, 3&nbsp;June 2024, the Retail Entitlement Offer was fully underwritten by Bell Potter Securities Limited and joint lead managed
by Bell Potter Securities Limited, Canaccord Genuity (Australia) Limited and Wilsons Corporate Finance Limited and <FONT STYLE="white-space:nowrap">co-managed</FONT> by CLSA Australia Pty Ltd. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.immutep.com &#8195;&#8195;&#8195;ABN: 90 009 237 889 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:4.00pt solid #70b682">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g717414g63s00.jpg" ALT="LOGO" STYLE="width:8.58542in;height:1.33958in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eligible Retail Shareholders should confirm the actual number of New Shares (including any Additional Shares)
issued to them before trading in such shares, and the sale by any Eligible Retail Shareholder of New Shares (including any Additional Shares) prior to receiving their holding statement is at their own risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Immutep wishes to thank all Eligible Retail Shareholders who participated in the Retail Entitlement Offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT IMMUTEP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the
Company&#146;s website www.immutep.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not
constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been registered under the US Securities Act of 1933 (the <B>US Securities Act</B>) or the securities laws of any state or
other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States unless they are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements
of the US Securities Act and applicable US state securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement contains certain &#147;forward-looking statements&#148; including but not
limited to projections, that are based on management&#146;s beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements can generally be identified by the use of forward-looking words such
as, &#147;expect&#148;, &#147;anticipate&#148;, &#147;likely&#148;, &#147;intend&#148;, &#147;should&#148;, &#147;could&#148;, &#147;may&#148;, &#147;predict&#148;, &#147;plan&#148;, &#147;propose&#148;, &#147;will&#148;, &#147;believe&#148;,
&#147;forecast&#148;, &#147;estimate&#148;, &#147;target&#148; &#147;outlook&#148;, &#147;guidance&#148; and other similar expressions within the meaning of securities laws of applicable jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the
significant volatility, uncertainty and disruption to equity and capital markets. Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change
without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this announcement are not
indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Immutep and its subsidiaries, and may involve significant elements of
subjective judgement and assumptions as to future events which may or may not be correct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.immutep.com &#8195;&#8195;&#8195;ABN: 90 009 237 889 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:4.00pt solid #70b682">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g717414g63s00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g717414g63s00.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !F@ H
M"0.O% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % #7( YI-V$W8X/4[BVU/6I8KNX\N&,87)P":QD[G%4E=D.F^%Y[V
M0NLRI;JWR,IR30HW%"FI%ZX@/A^]^UW)$X(VK@8H?NLN=-014T?67_X2(NOR
M0SG!7W[5:9A2J-2.]W#M6AZ:=T24 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "$X.* ,S5M<L]%MUFNWV
MAN@H ETS5K35K83VDFY3V]* +] !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 -SV!&: '"@ H * "@ H * "@ H 8_04F)K0\NUN![?59U<8W-N'XU
M@T>;5=F=/X9U6W33/+GD2/RS@$G&:J+L:4*B(?$-_9ZKBTAF&Y>=W:ID]2Z\
M^AA:-;%]=AB4[C&X;(]J<6<M*-Y'IH  K6YZJT0^J&% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #2.:!6U.?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?]=?ZT >ZP_ZB/\ W1_*@#G/'A3_ (1B8'[VY=OYB@#C/A^#_P )$S= $R:
M/6J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H :>O%+J(XSQN,O9>A#?TK.H<=:)8\$\VDQ']
MZE2*H*QF>,Q_Q-H<=H^?S-%0QQ".@\)?\@*,CID_SJZ9T89:$7C$?\2@?[]3
M4V)Q*]TQ_!?_ "$GQTV5--&>&5CM+H_Z+(>VTUL]CJJ?">868_XF\)Z#S@?U
MKG>YY\8^\>B:Q_R!YA_L5N]CNDO=.$\. C7;8$_Q<?D:PCN<=)>^>F-TQ71T
M/2EL>6ZS\VO78'_/4@USO<\Z<=3TC3O^/"'/]VMX['925D<KXX'^D6Q_V2/Y
MUE5.?$Q+O@O_ )!DO&/GITBL*K&!\1-/E%S#?(N8R K'TXK9G7+=%7PAXN@T
M:U-G?9$>[*L!0,T_$WB[2M2T26UMY7:1CD?)Q0!A_#\C_A)(^F=C=#[&@#L_
M'-FUWX>9D!+1-NH X'PIKL>AZDTLPS"XVL1VH [V3Q_HJ*-LC.Q/0"@#8OX8
M]8T22,#Y9X_EH \=B>Y\/:SOV[9H6. >XH ]$L?B#I4L"FY\R*3'/R&@"27Q
M_I"NL</FR,QP/EQ0!T@E$MJ) .&3./PH \,O'$6IS. 6 ?( H ],M/B!H[6Z
MB4R1NJ@%=N?UH Y/Q=XJ76U6WMP5MD.=W<F@#<^'6E2012W\R;3(-J@CJ,]:
M ._H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % "''Y4 ,,J"98B?G() ]J )* (HIXYES$P<9P<4 0SWUM#*$>
M3YO0#- %A7#H"O(- $$MW#!)MDD()]1Q0!.KJR!@00>F* &^:C3&$-\X&2/2
M@!(YXY=PCD#%>#CM0 1W$4A<*X)3[WM0 1SQRIYD<@9!D$B@!HNH3 TRR#RT
M')H <TJ1JK,V%) !]2:  SQK,L+,!*1D+0 JRH\CH#\R=?:@"N^H6L<NPS88
M'G"\#\: )I;F**,.Q^3KN% #(;V"<;HW)7&<XH ?YT?E&0N-@[T -ENHK=%9
MCC=]WWH 5;N)X3,&Q&O7(H ;!?6\YQ&^2>Q&* )9IHX$#2R! 3@$^M "O*D4
M1D8X4#)- $,-Y!,0%DR6&0IH >MQ$T1?>-H./I0 ]F#0,5Y!4T >%3?\A:3_
M *Z_UH ]VA_U$?\ NC^5 #Z "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M["#[-)J$9.7"C)]?EH I6JSVUM%%;(Q%U&#D]%;O_.@":* QZ-JMO&"2LD@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % "8H AGL[>Y(\Z)9,=-PS0 +:0H%"1JH7I@=* '>2NX.0I<=#MZ4
M,DLK:9P\L*.V,99<T 2K$J*%0;5'0#B@"*6RMYGW21*S#H2.10!-MY'/2@!!
M$JN7 ^8C!/M0 +$B*%"@ =!0 >4GS?*,MUH !&%4*O ' QV%  L2H6VC&XY/
MUH BCLK:)]\<*(_J!S0!+Y:[PV!N P#0 +$J%F4!6;J0.M $36-L[[F@0MG.
M=M $HC"@!> ..E  L:H@11A0, 4 ((4$7E[1M],4 -DM89E59(PRKT!% !':
M00QF.*-40_PJ,"@!Q@0A01]W&/:@!5B568@ %NOO0 T6Z -Q@N<L1QF@!PC
MXP/;B@ \M2X<@%@, T .*AN#R/2@"D='T\DG[)%N/?8,T 70 H ' % "T %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 )^-( _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&@ _&
M@ _&@ _&@ _&@ _&@ _&@!,BJ"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(
MH"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9%
M6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P
M9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(
MH"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9%
M6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P
M9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(
MH"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9% 6#(H"P9%
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MZ2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\
M"8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]8
M0?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.
M9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR
M/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI
M)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )
MCIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!
M_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD
M'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG_?(_
MQHYD'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.G>DG
M_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_  F.
MG>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?6$'_
M  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&CF0?
M6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]\C_&
MCF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=Z2?]
M\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\ "8Z=
MZ2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\
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MZ2?]\C_&CF0?6$'_  F.G>DG_?(_QHYD'UA!_P )CIWI)_WR/\:.9!]80?\
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M.1A[!A_PC&J?\\#^='(P]@P_X1C5/^>!_.CD8>P8?\(QJG_/ _G1R,/8,/\
MA&-4_P">!_.CD8>P8?\ ",:I_P \#^='(P]@P_X1C5/^>!_.CD8>P8?\(QJG
M_/ _G1R,/8,/^$8U3_G@?SHY&'L&'_",:I_SP/YT<C#V##_A&-4_YX'\Z.1A
M[!A_PC&J?\\#^='(P]@P_P"$8U3_ )X'\Z.1A[!A_P (QJG_ #P/YT<C#V##
M_A&-4_YX'\Z.1A[!A_PC&J?\\#^='(P]@P_X1C5/^>!_.CD8>P8?\(QJG_/
M_G1R,/8,]+Q70>I8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
M,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
M,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
M,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
M,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
M,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
M,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
M,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8,4!8
(,4!8,4!8_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
